These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32526069)

  • 1. Conformational changes in a Vernier zone region: Implications for antibody dual specificity.
    Arslan M; Karadag D; Kalyoncu S
    Proteins; 2020 Nov; 88(11):1447-1457. PubMed ID: 32526069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
    Bostrom J; Yu SF; Kan D; Appleton BA; Lee CV; Billeci K; Man W; Peale F; Ross S; Wiesmann C; Fuh G
    Science; 2009 Mar; 323(5921):1610-4. PubMed ID: 19299620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High affinity antigen recognition of the dual specific variants of herceptin is entropy-driven in spite of structural plasticity.
    Bostrom J; Haber L; Koenig P; Kelley RF; Fuh G
    PLoS One; 2011 Apr; 6(4):e17887. PubMed ID: 21526167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
    Lu D; Jimenez X; Witte L; Zhu Z
    Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of antibody structural epitopes via random peptide library screening and next generation sequencing.
    Ibsen KN; Daugherty PS
    J Immunol Methods; 2017 Dec; 451():28-36. PubMed ID: 28827189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528.
    Makabe K; Nakanishi T; Tsumoto K; Tanaka Y; Kondo H; Umetsu M; Sone Y; Asano R; Kumagai I
    J Biol Chem; 2008 Jan; 283(2):1156-66. PubMed ID: 17947238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies.
    Harms BD; Kearns JD; Iadevaia S; Lugovskoy AA
    Methods; 2014 Jan; 65(1):95-104. PubMed ID: 23872324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
    Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
    J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
    Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dual-specificity therapeutic antibodies].
    Winckler T
    Pharm Unserer Zeit; 2009; 38(5):395-6. PubMed ID: 19711313
    [No Abstract]   [Full Text] [Related]  

  • 12. Immunology. Two-in-one designer antibodies.
    Parren PW; Burton DR
    Science; 2009 Mar; 323(5921):1567-8. PubMed ID: 19299606
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimization of therapeutic antibodies by predicting antigen specificity from antibody sequence via deep learning.
    Mason DM; Friedensohn S; Weber CR; Jordi C; Wagner B; Meng SM; Ehling RA; Bonati L; Dahinden J; Gainza P; Correia BE; Reddy ST
    Nat Biomed Eng; 2021 Jun; 5(6):600-612. PubMed ID: 33859386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for antigen recognition by methylated lysine-specific antibodies.
    Ishii M; Nakakido M; Caaveiro JMM; Kuroda D; Okumura CJ; Maruyama T; Entzminger K; Tsumoto K
    J Biol Chem; 2021; 296():100176. PubMed ID: 33303630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deep Sequencing-guided Design of a High Affinity Dual Specificity Antibody to Target Two Angiogenic Factors in Neovascular Age-related Macular Degeneration.
    Koenig P; Lee CV; Sanowar S; Wu P; Stinson J; Harris SF; Fuh G
    J Biol Chem; 2015 Sep; 290(36):21773-86. PubMed ID: 26088137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combinatorial approach to engineering a dual-specific metal switch antibody.
    Fanning SW; Murtaugh ML; Horn JR
    Biochemistry; 2011 Jun; 50(23):5093-5. PubMed ID: 21568282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
    Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
    Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering aggregation-resistant antibodies.
    Perchiacca JM; Tessier PM
    Annu Rev Chem Biomol Eng; 2012; 3():263-86. PubMed ID: 22468604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies.
    Kipriyanov SM; Moldenhauer G; Braunagel M; Reusch U; Cochlovius B; Le Gall F; Kouprianova OA; Von der Lieth CW; Little M
    J Mol Biol; 2003 Jun; 330(1):99-111. PubMed ID: 12818205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
    Shen J; Vil MD; Jimenez X; Zhang H; Iacolina M; Mangalampalli V; Balderes P; Ludwig DL; Zhu Z
    J Immunol Methods; 2007 Jan; 318(1-2):65-74. PubMed ID: 17126853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.